What are the indications, dosing regimens, routes of administration, and contraindications for sumatriptan in the acute treatment of migraine?

Sumatriptan for Acute Migraine Treatment

Sumatriptan is indicated as acute treatment for migraine with or without aura in adults, and should be combined with an NSAID or acetaminophen for optimal efficacy, not used as monotherapy initially. 1, 2

Indications

Sumatriptan is FDA-approved specifically for:

• Acute treatment of migraine with or without aura in adults 2
• Must have a clear diagnosis of migraine established before use
• NOT indicated for migraine prevention 2
• NOT indicated for cluster headache (despite off-label use) 2

Critical caveat: If a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis before treating subsequent attacks 2.

Dosing Regimens and Routes of Administration

Oral Route (Most Common)

• Initial dose: 25 mg, 50 mg, or 100 mg tablet 2
• 100 mg is the most effective oral dose with NNT of 5.1 for pain-free response at 2 hours 3
• 50 mg has similar efficacy (NNT 3.2 for headache relief) but less robust data 3
• 25 mg is less effective (NNT 7.5 for pain-free response) 3
• Maximum daily dose: 200 mg 2
• Separate doses by at least 2 hours 2
• A second dose should only be considered if some response to the first dose was observed 2

Subcutaneous Route (Most Effective)

• Standard dose: 6 mg subcutaneous 2, 4
• 70-80% of patients achieve relief within 1-2 hours 5, 6
• Highly likely to be effective based on multiple class I studies 4
• Should be offered to eligible adults in ED settings (Level B recommendation) 7
• Faster onset than oral formulations 6

Intranasal Route

• Available but less commonly used
• Superior to placebo for headache relief at 2 hours (RR 1.58) 8
• Associated with six-fold increase in taste disturbance compared to placebo 8

Rectal Route

• Doses of 12.5 mg and 25 mg have best efficacy/safety profile 9
• 25 mg achieved 72% headache relief within 2 hours vs 37% with placebo 9
• Rapid absorption (median tmax = 1.0 hour) 9

Treatment Algorithm per 2025 ACP Guidelines

Step 1: Start with adequate-dose NSAID or acetaminophen alone 1

Step 2: If inadequate response to Step 1, add a triptan (including sumatriptan) to an NSAID, or to acetaminophen when NSAIDs are contraindicated 1

Step 3: Begin treatment as early as possible after migraine onset using combination therapy (triptan + NSAID/acetaminophen) to improve efficacy 1

Special situation: Use nonoral triptan (subcutaneous or intranasal sumatriptan) with an antiemetic in patients with severe nausea or vomiting 1

Contraindications (Absolute)

Cardiovascular contraindications 2:

• History of coronary artery disease or coronary artery vasospasm
• Previous myocardial infarction
• Prinzmetal's (variant) angina
• Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
• History of stroke or transient ischemic attack
• Hemiplegic or basilar migraine
• Peripheral vascular disease
• Ischemic bowel disease
• Uncontrolled hypertension

Drug interaction contraindications 2:

• Recent use (within 24 hours) of another 5-HT1 agonist (another triptan) or ergotamine-containing medication
• Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor

Other contraindications 2:

• Hypersensitivity to sumatriptan (angioedema and anaphylaxis reported)
• Severe hepatic impairment
• Maximum single dose should not exceed 50 mg in mild to moderate hepatic impairment 2

Critical Safety Warnings

Medication Overuse Headache

Use sumatriptan no more than 10 days per month to prevent medication overuse headache 1. This threshold is lower than for NSAIDs (≥15 days/month) 1.

Chest Symptoms

• Chest pain/tightness/pressure occurs in 3-5% of patients 5, 6
• Generally not associated with myocardial ischemia, but evaluate high-risk patients for coronary artery disease 2
• Discontinue if myocardial ischemia occurs 2

Common Adverse Events

Oral formulation 3:

• Nausea, vomiting, malaise, fatigue, dizziness
• NNH = 7.1 for any adverse event with 100 mg dose

Subcutaneous formulation 6:

• Injection site reactions in ~40% (reduced with auto-injector)
• Higher overall adverse event rate than oral

Pregnancy and Lactation

• Contraindicated in pregnant and lactating women per guideline applicability 1
• Discuss adverse effects during pregnancy and lactation with people of childbearing potential 1

Clinical Pearls

Headache recurrence: Approximately 40% of initial responders experience headache recurrence within 24 hours, but the majority respond well to a second dose 6, 3.

Route selection for severe attacks: Consider subcutaneous sumatriptan for moderate to severe attacks requiring rapid relief, especially in ED settings where it has Level B evidence 4, 7.

Do NOT use during migraine aura 5 - wait until headache phase begins.

Avoid opioids: The 2025 ACP guideline explicitly states "Do not use opioids or butalbital for the treatment of acute episodic migraine" 1. Hydromorphone must not be offered in ED settings (Level A) 4.